News and Analysis
Nature Reviews Drug Discovery 6, 865-866 (November 2007) | doi:10.1038/nrd2442
Fresh from the Pipeline: Retapamulin
Robert S. Daum1, Santwana Kar2 & Peter Kirkpatrick3
Top of page
Abstract
Retapamulin (Altabax; GlaxoSmithKline) is the first in a new class of antibacterial drugs known as pleuromutilins to be approved for use in humans. It was approved by the US FDA for the topical treatment of impetigo, a skin infection caused by bacteria, in April 2007, and approved in Europe (where it will be marketed as Altargo) for the treatment of impetigo and infected small lacerations, abrasions or sutured wounds in June 2007.
Author affiliations
-
Robert S. Daum is at the Section of Infectious Diseases, Department of Pediatrics, University of Chicago, Chicago, USA.
Email: rdaum@peds.bsd.uchicago.edu -
Santwana Kar is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK.
Email: skar@uk.imshealth.com -
Peter Kirkpatrick is at Nature Reviews Drug Discovery.
Email: p.kirkpatrick@nature.com
